Thymosin Beta-4 Protects Kidneys from Ischemic Injury Through Anti-Inflammatory and Antioxidant Effects | Research

The takeaway

Thymosin β-4 significantly reduced ischemic acute kidney injury in rats by inhibiting oxidative stress, inflammation, apoptosis, and extracellular matrix remodeling, with effects whether given before or during ischemia.

p<0.001
significance level for Tβ4's reduction of kidney injury markers including creatinine, BUN, and inflammatory cytokines

What the researchers found

Tβ4 significantly reduced caspase-9, MMP-9 activity, hyaluronan, oxidative stress, and inflammation markers while restoring antioxidant levels in both pre-treatment and peri-ischemic treatment groups. Serum creatinine and BUN were significantly reduced (p<0.001).

Why it matters

Ischemic AKI occurs commonly during surgery and in critical illness. Having an effective protective peptide that works even when given just before reperfusion could transform kidney injury prevention in clinical settings.

The numbers in context

32 rats; 4 groups (8/group); 90-min ischemia; TB4 pre- and post-treatment both significantly reduced kidney damage.

How the study worked

Rat model: 4 groups (n=8): sham, I/R (90 min ischemia + 3h reperfusion), Tβ4 pre-treatment + I/R, and Tβ4 during I/R. Measured renal function (Cr, BUN), histology, oxidative stress panel, inflammatory cytokines, caspase-9, MMP-9, and hyaluronan.

Who was studied

Rats with ischemic acute kidney injury (90-min aortic occlusion + 3-hr reperfusion)

What this study cannot tell us

Rat model with relatively short reperfusion period (3h). Long-term kidney recovery not assessed. Optimal human dosing and timing need investigation. Tβ4 is not yet approved for clinical use.

How to read the evidence

Well-designed preclinical study with multiple outcome measures and two treatment timing groups. Strong effect sizes but requires human validation.

When this study was published

Published in 2021. Thymosin beta-4 continues to be investigated for organ protection across multiple systems.

The bigger picture

Thymosin beta-4 is emerging as a multi-organ protectant — with evidence for corneal, cardiac, and now renal protection. The consistent mechanism of anti-inflammation and anti-apoptosis across organs suggests a fundamental cytoprotective role.

Questions still open

Could Tβ4 be given prophylactically before surgeries with high AKI risk?
How does Tβ4's kidney protection compare to existing strategies like remote ischemic preconditioning?
Would Tβ4 protect against other forms of AKI beyond ischemic injury?

Common questions

What causes ischemic kidney injury?

Ischemic AKI occurs when blood flow to the kidneys is temporarily interrupted — during surgery, trauma, or severe illness. When blood flow returns (reperfusion), it paradoxically causes additional damage through oxidative stress and inflammation.

Why is it important that Tβ4 works when given during ischemia?

In many clinical situations, kidney ischemia can't be predicted in advance. A treatment that works when given at the time of injury (not just as prevention) would be far more useful in emergency and surgical settings.

Read the original research

The Protective Effects of Thymosin-β-4 in a Rat Model of Ischemic Acute Kidney Injury.

Journal of investigative surgery : the official journal of the Academy of Surgical Research, 34(6), 601-609

View on PubMed ↗Publisher’s paper ↗

Citation

Aksu, Ugur; Yaman, Onur M; Guner, Ibrahim; Guntas, Gulcan; Sonmez, Fuat; Tanriverdi, Gamze; Eser, Mediha; Cakiris, Aris; Akyol, Sibel; Seçkin, İsmail; Uzun, Hafize; Yelmen, Nermin; Sahin, Gulderen. (2021). The Protective Effects of Thymosin-β-4 in a Rat Model of Ischemic Acute Kidney Injury.. Journal of investigative surgery : the official journal of the Academy of Surgical Research, 34(6), 601-609. https://doi.org/10.1080/08941939.2019.1672841